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ABSTRACT
Introduction: The aim of the present study was
to describe clinical outcomes in a real-world
population of Swiss patients with long-stand-
ing, poorly controlled type 2 diabetes after
switching to IDegLira [a combination of insulin
degludec (IDeg) and liraglutide (Lira)].
Methods: This was a prospective, open-label,
single-center observational follow-up at the
Cabinet Medical de Diabe´tologie, Lausanne,
Switzerland, of 61 patients [HbA1c 9.2%
(77 mmol/mol) and 56.1 U total insulin] initi-
ated with IDegLira at 20 dose steps (20 U IDeg/
0.72 mg Lira), except in insulin-naı¨ve patients
who began treatment at 16 dose steps. There-
after, the dose was titrated by four dose steps
once weekly, according to individualized fasting
blood glucose targets. Information about gly-
cemic control, total insulin dose, weight, and
blood pressure, along with any adverse events,
was collected from medical records and patient
reports during clinic visits at baseline,
3 months, and end of follow-up.
Results: Over 6 months of follow-up, mean
HbA1c improved (decrease of 1.7%) to 7.5%
with concomitant weight loss. Switching to
IDegLira resulted in a lower (-14.6 U) total
insulin dose compared with baseline for those
patients previously on insulin. There were no
episodes of severe hypoglycemia during treat-
ment with IDegLira. There were small decreases
in both mean systolic and mean diastolic blood
pressure with IDegLira. Six patients discontin-
ued treatment early because of adverse gas-
trointestinal events with IDegLira.
Conclusion: Switching to IDegLira, mostly
from regimens using insulin in conjunction
with oral antidiabetic medications in a real-
world population of patients with type 2 dia-
betes, resulted in improved glucose control with
a lower insulin dose and weight loss.
Keywords: IDegLira; Incretin; Insulin;
Observational study; Type 2 diabetes
INTRODUCTION
Typically, patients with newly diagnosed type 2
diabetes (T2D) are initially encouraged to
attempt to lower their blood glucose with
nutrition and lifestyle management. As a result
of the progressive pathophysiology of T2D,
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however, further treatment intensification will
eventually be required. The next step usually
involves addition of oral antidiabetic medica-
tions, often followed by exogenous insulin
therapy. However, patients may resist treatment
intensification, particularly when insulin is
involved, because of concerns about hypo-
glycemia, body weight gain, and/or the com-
plexity of such regimens. Incretin-based
therapies such as dipeptidyl peptidase-4 inhibi-
tors or glucagon-like peptide 1 (GLP-1) receptor
agonists represent another option: these drugs
carry a low risk of hypoglycemia and typically
do not cause weight gain [1, 2].
IDegLira (Xultophy, Novo Nordisk A/S,
Bagsvaerd, Denmark) is a fixed-ratio combina-
tion of insulin degludec (IDeg; 100 U/mL) and
liraglutide (Lira; 3.6 mg/mL). Insulin degludec
is a basal insulin with an ultra-long duration of
action and a flat pharmacodynamic profile
[3, 4], and is associated with a lower risk of
hypoglycemia than insulin glargine U100 [5, 6].
Liraglutide is a human GLP-1 analogue given
once daily; it stimulates insulin secretion and
lowers glucagon secretion in a glucose-depen-
dent fashion, thus posing a low risk of hypo-
glycemia while helping to control both fasting
and post-meal glucose levels [7].
Liraglutide delays gastric emptying and
reduces feelings of hunger. It is also used as a
treatment for obesity, and therefore is often
associated with weight loss in patients with
diabetes [8, 9]. The pharmacokinetic properties
of the two individual components, insulin
degludec and liraglutide, are preserved in the
fixed-ratio combination product IDegLira [10].
IDegLira is administered in dose steps (1 U
insulin degludec and 0.036 mg liraglutide) up to
a maximum of 50 dose steps, corresponding to
50 U of insulin degludec and 1.8 mg of
liraglutide.
The complementary mode of action of its
two components means that IDegLira has the
potential to be advantageous for patients with
T2D who need to intensify therapy to achieve
better glycemic control, but who may be reluc-
tant to do so because of concerns about hypo-
glycemia, weight gain, and/or treatment
complexity. In large, randomized, controlled,
treat-to-target trials both in insulin-naı¨ve
[11, 12] and insulin-experienced patients
[13, 14], IDegLira has been shown to improve
glycemic control without increasing body
weight or risk of hypoglycemia.
The beneficial effects shown in clinical trials,
however, are achieved in cohorts with strictly
defined inclusion and exclusion criteria, so it is
also important to gauge how well IDegLira will
perform in the more heterogeneous populations
of patients encountered in real-world practice.
Several reports indicate that, when used indi-
vidually in real-world populations, insulin
degludec [15–18] and liraglutide [19, 20] each
retain the benefits demonstrated in prior ran-
domized controlled trials. This study adds to the
body of real-world data by describing outcomes
in Swiss patients with a long duration of T2D
who were empirically selected for treatment
with IDegLira.
METHODS
This was a prospective, open-label, single-center
observational follow-up at the Cabinet Medical
de Diabe´tologie in Lausanne, Switzerland, of all
consecutive patients starting IDegLira between
December 2014 and July 2015.
Patients began treatment with IDegLira for
the following indications: not being well
controlled under current treatment (HbA1c
greater than 8.0%), current treatment being
too complicated for the patient (more than
two oral antidiabetic medications and more
than one injection daily), or it was believed
the patient would benefit from the addition of
the liraglutide component of IDegLira for
weight management. No patients were exclu-
ded; however, it should be noted that in
Switzerland, treatment with GLP-1 receptor
agonists is reimbursed only for those patients
whose body mass index (BMI) exceeds
28 kg/m2. All procedures followed were in
accordance with the ethical standards of the
responsible committee on human experimen-
tation (institutional and national) and with
the Helsinki Declaration of 1964, as revised in
2013 [21]. Informed consent was obtained
from all patients for being included in the
study. The study was approved by the ethics
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committee for research in human beings in
Lausanne, Switzerland.
IDegLira was initiated at 20 dose steps
(20 U IDeg/0.72 mg liraglutide), except in insu-
lin-naı¨ve patients who began treatment at 16
dose steps. Thereafter, the dose was titrated in
four dose steps once weekly, according to indi-
vidualized fasting blood glucose targets. The
individual HbA1c target was set according to the
European Association for the Study of Diabetes
(EASD) recommendations. This value was con-
verted to fasting plasma glucose for the patient.
Patients were instructed to increase the dose of
IDegLira by increments of four dose steps per
week until achievement of the negotiated and
individualized target.
For those patients requiring high doses of
insulin (more than 50 units), a transition phase
was included with addition of a slow-acting
insulin during titration of IDegLira. If a patient
reached the maximum of 50 dose steps and had
still not reached good control, a second basal
insulin was added (this was only necessary for
one patient). Other concomitant therapies were
allowed on the basis of physician and patient
preference. At the time of switching treatment,
each patient received a reminder on recom-
mendations for following a balanced diet
appropriate for type 2 diabetes, as well as
encouragement to engage in at least 30 min of
physical activity daily.
Information about glycemic control, total
insulin dose, weight and blood pressure, as well
as any adverse events, was collected from med-
ical records and patient reports during clinic
visits at baseline, at 3 months, and at the end of
follow-up. Severe hypoglycemia was defined as
events requiring the assistance of a third party.
RESULTS
A total of 61 patients with T2D were followed
up, with six (one male, five female) discontin-
uing treatment early because of adverse gas-
trointestinal events such as nausea and
vomiting. Baseline demographics and prior
diabetes treatment for all patients are shown in
Table 1. Almost all patients (n = 56, 91.8%) had
been using insulin, and the population could be
characterized as very overweight (mean BMI
34.3 kg/m2) and in poor glycemic control
(mean HbA1c 9.17%). Most patients continued
with other concomitant therapy (sulfonylurea
only: n = 1, 1.6%; metformin only: n = 36,
59.0%; metformin ? sodium-glucose trans-
porter-2 inhibitors: n = 9, 14.8%; met-
formin ? sulfonylurea: n = 2, 3.3%; and
metformin ? basal insulin: n = 1, 1.6%). Twelve
(19.7%) patients did not use any other therapy
besides IDegLira for their diabetes.
There were several clinically important ben-
efits from switching to IDegLira for the 55
patients who completed 6 months of follow-up:
mean HbA1c improved (decrease of 1.7%) to
7.5% (Fig. 1a) and there was concomitant
weight loss (Fig. 1b). Furthermore, switching to
IDegLira resulted in a lower (-14.6 U) total
insulin dose compared with baseline for those
patients previously on insulin (Fig. 1c). Only
one patient required a second basal insulin. A
total of 20/61 (32.8%) of all patients and 20/55
(36.4%) of those who continued treatment
required the maximum dose (50 dose steps) of
IDegLira. There were small decreases in both
mean systolic and mean diastolic blood pressure
after treatment with IDegLira (Fig. 1d). When
data from the six patients who did not complete
follow-up were included in the calculation of
baseline values, the decreases in HbA1c, insulin
dose, and blood pressure did not change sub-
stantially. However, the magnitude of mean
weight reduction achieved was lower (-0.4 kg).
For the four non-completers for whom baseline
weight was available, the mean value (77.5 kg)
was much lower than for the group of com-
pleters (97.9 kg).
There were no episodes of severe hypo-
glycemia during treatment with IDegLira in
these Swiss patients.
DISCUSSION
Before starting treatment with IDegLira, this
real-world population of mostly insulin-experi-
enced (91.9%) Swiss patients had a longer
duration of diabetes (12.5 years), poorer glucose
control (HbA1c 9.2%), and greater mean body
weight (96.5 kg) compared with patients
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enrolled in randomized trials of a comparable
duration of follow-up (26–52 weeks)
[11, 13, 14].
As was reported in the randomized clinical
trials of IDegLira, in this follow-up of Swiss
patients with T2D of relatively long duration,








Age (years) 57.3 (range 25–80)
Duration of diabetes (years) 12.5 (range 1–31) 11.5 14.2
Weight (kg) 96.5 103.2 87.5
BMI (kg/m2) 34.3 33.9 34.9
HbA1c (%) 9.2 9.0 9.4
HbA1c (mmol/mol) 77 75 79
Systolic blood pressure (mmHg) 146.4 148.5 142.5
Diastolic blood pressure (mmHg) 88.4 90.8 84.3
Previous oral treatment (n, %)b
Metformin 23 (37.7)
Metformin ? sitagliptin 18 (29.5)
Gliclazide 12 (19.7)
Liraglutide 8 (13.1)
Metformin ? saxagliptin 5 (8.2)
Linagliptin 3 (4.9)
Otherc 10 (16.4)
Previous insulin treatment (n, %)
Insulin degludec 30 (49.2)
NPH 9 (14.8)
Insulin glargine 5 (8.2)
Insulin aspart/protamine crystallized insulin aspart 4 (6.6)
Insulin aspart/insulin degludec mix 3 (4.9)
Insulin detemir 3 (4.9)
Insulin lispro/insulin lispro protamine/NPH 2 (3.3)
None 5 (8.2)
BMI body mass index, HbA1c glycated hemoglobin, IDegLira insulin degludec/liraglutide, NPH neutral protamine
Hagedorn
a Values are means unless otherwise speciﬁed
b Numbers add to[100% owing to some patients being on multiple treatments
c B2 patients on any given medication
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mean HbA1c decreased after approximately
26 weeks of treatment. The reduction in
HbA1c in these poorly controlled patients
(-1.7%) was of a slightly lesser extent than
those reported from the more restricted
patient populations enrolled in randomized,
treat-to-target trials (-1.8% to -1.9%)
[11, 13, 14]. Furthermore, the improvement in
HbA1c in the Swiss patients was detectable at
approximately 12 weeks (Fig. 1a), which is
consistent with data from randomized clinical
trials [22]. Unfortunately, as there were no
observations in the period between switching
to IDegLira and 12 weeks, it is not possible to
determine precisely when the decrease began.
These results are also consistent with a post
hoc analysis of two randomized controlled
trials, which showed that the reduction in
HbA1c was largely independent of disease
duration or previous insulin dose [23]. By
comparison, the reduction in weight among
those patients completing follow-up (-1.9 kg)
in this study was greater than that reported in
two randomized trials, -0.5 kg [11] and
-1.4 kg [14], but less than that reported for
another trial (-2.7 kg [13]).
It should be mentioned that, very often, a
seasonal weight variation is observed, with an
increase during winter and a decrease during
summer. Despite the fact that the 6-month
observation period for these patients went from
the beginning of winter to spring, there was a
trend towards weight loss.
The decrease in systolic blood pressure in
these patients (9.1 mmHg) is also consistent
with results from randomized trials of liraglu-
tide alone [7] and IDegLira [14].
The absence of any episodes of severe hypo-
glycemia is consistent with previously reported
randomized trials of IDegLira in patients previ-
ously treated with insulin [13, 14]. In these
larger-scale studies, only one episode of severe
hypoglycemia was reported and this occurred
during exercise (mountain climbing) and was
resolved after consumption of a sweet beverage
[13].
Fig. 1 Glucose control (a), body weight (b), insulin dose
(c), and blood pressure (d) before and after switching to
IDegLira in 55 Swiss patients who completed follow-up.
Red dotted line in a shows normal value for HbA1c (5.5%).
HbA1c glycated hemoglobin, IDegLira insulin degludec/
liraglutide, D mean change from baseline
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Among the limitations of this study is the
small sample size. This was fixed on the basis of
the constraint of the observation period. For the
chosen observation period, the number of
patients included is representative of the vol-
ume of consultations performed by a private
practice in a Swiss city. A longer period of
observation would probably have better con-
solidated the data but it would have required a
longer period and a greater workforce so as not
to interfere with the usual functioning of the
private practice. Data on adverse events such as
hypoglycemia were not systematically solicited,
nor were reported events assessed. Instead, they
were recorded only if patients mentioned them
during a follow-up visit. However, patients were
generally very open about their experience with
IDegLira during follow-up visits.
Patients initiated therapy at a higher dose of
IDegLira (20 dose steps for insulin experienced,
16 dose steps for insulin naı¨ve) than is recom-
mended in the IDegLira prescribing informa-
tion (16 dose steps for insulin experienced and
10 dose steps when transferring from oral ther-
apy) [24]. This shows how clinical practice in a
real-world setting differs from clinical trials. In a
clinical trial, where patients are monitored clo-
sely and regularly, titration can be slower, and
frequent contact with participants can be help-
ful in ensuring treatment compliance. In real-
life practice, where visits and follow-up are
much less frequent, it may be necessary to be
more aggressive in the titration process so that
patients sense improvement and therefore
retain the motivation to continue with treat-
ment. The trade-off for starting with a higher
dose of IDegLira, of course, may be in the
inability of some patients to continue therapy
because of gastrointestinal side effects. Given
the lower body weight among patients who
discontinued in this follow-up study, a more
individualized titration schedule might be war-
ranted, taking into account factors such as body
weight. Despite the starting dose of IDegLira in
this study being higher than that recom-
mended, patients’ total insulin requirements
were nevertheless reduced from those at base-
line over 6 months, with the achievement of an
improved and acceptable mean HbA1c. Had a
treat-to-target approach been used, it is likely
that HbA1c could have been further reduced.
Some aspects of diabetes treatment, which are
just as important as glycemic control, have not
been formally evaluated in this observational
analysis, but deserve to be mentioned here.
According to patients’ feedback, the process of
changing treatment to IDegLira was itself helpful
by increasing their motivation to better manage
their diabetes. Examples include being more
careful about what they eat and when, and
engaging in more frequent self-measured blood
glucose testing. This in turn has an impact on
improving glycemia. For some patients, concur-
rent stressful life events (e.g., serious illness in a
spouse, divorce) may have interfered with opti-
mal diabetes management. In others, while
switching treatment did not immediately result
in improvements in glycemic control, there were
nevertheless important benefits with respect to
quality of life (e.g., being able to engage in more
regular exercise owing to feeling less sick).
CONCLUSION
Switching to IDegLira, mostly from regimens of
other insulin treatments in conjunction with
oral antidiabetic medications in a real-world
population in patients treated for T2D, resulted
in improved glucose control with a lower insu-
lin dose and without weight gain.
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